Guided Therapeutics (GTHP) Accumulated Expenses (2010 - 2026)

Guided Therapeutics has disclosed Accumulated Expenses across 17 years of filings, most recently posting $1.2 million for Q2 2026.

• In Q2 2026, Accumulated Expenses changed N/A year-over-year to $1.2 million; the TTM figure through Jun 2026 stood at $1.2 million (changed N/A YoY), while the FY2025 annual figure was $1.2 million, changed N/A from the prior year.
• Accumulated Expenses came in at $1.2 million for Q2 2026 at Guided Therapeutics, up from $1.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $1.2 million in Q4 2022 to a low of $780000.0 in Q1 2024.
• Average Accumulated Expenses over 5 years is $1.0 million, with a median of $1.1 million recorded in 2022.
• The largest YoY upside for Accumulated Expenses was 3087.13% in 2022 against a maximum downside of 74.91% in 2022.
• Over 5 years, Accumulated Expenses stood at $1.2 million in 2022, then declined by 14.35% to $1.1 million in 2023, then fell by 13.58% to $923000.0 in 2024, then increased by 26.76% to $1.2 million in 2025, then grew by 6.15% to $1.2 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $1.2 million in Q2 2026, $1.1 million in Q1 2026, and $1.2 million in Q4 2025.